38 results about "Eb virus" patented technology

The invention belongs to the technical field of biological genetic engineering, and particularly relates to a mouse model construction scheme capable of reproducing a key phenotype of hemophagocytic syndrome, which comprises the following steps: inserting a loxP-STOP-loxP-LMP1 conditional expression cassette into a Rosa26 safe port site in a fixed point manner to obtain an Lmp1cKI mouse strain; and hybridizing the mouse with an Ncr1-Cre transgenic mouse of NK cell specific expression Cre recombinase. In a double transgenic offspring (Lmp1Ncr1-Cre), STOP fragments are cut off by Cre enzyme, and continuous high expression of EB virus LMP1 protein in NK cells is driven. The model does not need chemical induction or immune intervention, and typical hemophagocytic syndrome phenotypes, namely serum IL-6, TNF-alpha and IFN-gamma, spontaneously appear within 7-9 days after young rats are born; the body weight is reduced and the survival rate is obviously reduced; the proportion of lymphocytes is sharply reduced; and NK cells are depleted. The invention provides a stable and reliable tool for hemophagocytic syndrome pathogenesis research, drug screening and treatment evaluation.

The invention relates to a detection kit for nasopharynx cancer diagnosis and screening, which comprises an immunochromatography detection card, and the immunochromatography detection card comprises a reagent for detecting EB virus antigen and antibody through a colloidal gold labeling method. The invention also relates to application of the detection card and the EB virus antigen-antibody in preparation of a detection kit or a detection card for nasopharynx cancer diagnosis and screening.

The invention discloses an NbE7 single-domain antibody, an NbE7-TAT fusion single-domain antibody and application of the NbE7 single-domain antibody and the NbE7-TAT fusion single-domain antibody, the NbE7 single-domain antibody is used for being specifically combined with an EB virus nuclear antigen, the NbE7 single-domain antibody is composed of a framework region FR and a complementary determining region CDR, and the complementary determining region CDR comprises a CDR1 shown in SEQ ID NO.1, a CDR2 shown in SEQ ID NO.2 and a CDR3 shown in SEQ ID NO.3. The NbE7 single-domain antibody is used for being specifically combined with an EB virus nuclear antigen. The NbE7-TAT fusion single-domain antibody is a fusion protein of an NbE7 single-domain antibody and a TAT peptide fragment of an HIV-1 virus. The NbE7 single-domain antibody and the NbE7-TAT fusion single-domain antibody provided by the invention provide a new thought for the development of drugs for treating EBV latent infection and EB virus related tumors.

The invention provides an application of alkannin in treatment of nasopharyngeal carcinoma infected by EB (Epstein-Barr) virus. A large number of studies find that compared with nasopharyngeal carcinoma cells not infected with EB viruses, alkannin is more sensitive to the nasopharyngeal carcinoma cells infected with the EB viruses, and IC50 is lower. The shikonin can better inhibit the proliferation and migration ability of nasopharyngeal carcinoma cells infected by EB virus, and promote the apoptosis of the nasopharyngeal carcinoma cells. In addition, the in-vivo anti-tumor curative effect of the shikonin on the nasopharyngeal carcinoma cell xenotransplantation tumor model infected by the EB virus is obviously superior to that of the nasopharyngeal carcinoma cell xenotransplantation tumor model not infected by the EB virus. After treatment with alkannin, the tumor growth ability of the nasopharyngeal carcinoma cell xenotransplantation tumor model mouse infected by the EB virus is obviously weaker than that of the nasopharyngeal carcinoma cell xenotransplantation tumor model mouse not infected by the EB virus. In addition, alkannin has no obvious side effect when used for treating nasopharyngeal carcinoma caused by EB virus, and is high in safety.

The application belongs to the technical field of antibodies, and discloses a monoclonal antibody Fab5 for recognizing EB virus gB protein and application thereof. The monoclonal antibody or antigen-binding fragment thereof has high affinity to the gB protein and can significantly inhibit the infection of EBV on epithelial cells and B cells, and the epitope of the Fab5 binding to the gB is determined through structural analysis. The antibody can be used for detecting the presence or level of the gB protein in a sample, detecting the EB virus, diagnosing diseases caused by the EB virus infection, preventing the EB virus infection and / or treating and / or preventing diseases caused by the EB virus infection.

The invention relates to the technical field of biology, in particular to an anti-EB (Epstein-Barr) virus Rta protein antibody as well as an antigen binding fragment and application thereof. The invention provides an antibody capable of specifically recognizing EB (Epstein-Barr) virus Rta protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprises complementary determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, and the amino acid sequences of the complementary determining regions are respectively as follows: GFTFSSSYG, ISSSRYT, ARHLLSGTSSFDC, KSLHSNGNTY, YMS and MQSLEYPFT. The antibody or the antigen binding fragment thereof can be used as a positive control and a calibrator in a nasopharyngeal carcinoma in-vitro diagnostic kit, so that the problem of batch-to-batch difference existing in nasopharyngeal carcinoma positive serum is avoided, and the production cost of the nasopharyngeal carcinoma detection kit is reduced.

The invention relates to a kit for early differential diagnosis of EBV-HLH and a method for auxiliary diagnosis of EBV-HLH. The kit comprises an EBV nucleic acid detection reagent and a miRNA-375 detection reagent. The kit provided by the invention is used for combined detection of EBV-DNA and miRNA-375 in a detection sample, and when an EBV-DNA detection result is greater than 5000 copies / mL and a miRNA-375 detection CT value is less than 35, suspected EBV-HLH is diagnosed. The invention not only provides a specific diagnostic index for EB infected diseases, but also serves as a reliable auxiliary diagnostic tool for EBV-HLH and other EB virus infection related diseases. When the kit provided by the invention is used for identifying and diagnosing EBV-HLH, the sensitivity and the accuracy are higher.

The present application belongs to the field of medicine, and particularly relates to an EBNA1 inhibitor. The small molecule inhibitor recorded in the present application is proved by surface plasmon resonance (SPR) analysis to interact with EBNA1 in vitro and have high affinity, significantly inhibit the function of EBNA1 at the cell level, significantly down-regulate the copy number of the Epstein-Barr virus (EBV) genome of PBMC of a nasopharyngeal carcinoma patient in vitro, have good biological safety in mice, provide a new treatment strategy for patients with EB virus positive tumors, and have far-reaching clinical significance and popularization.

The invention discloses a 5E2-12 monoclonal antibody and application thereof, the 5E2-12 monoclonal antibody is specifically combined with EB virus nuclear antigen and comprises VHCDR1-3 of a heavy chain variable region and VLCDR1-3 of a light chain variable region, the amino acid sequences of VHCDR1, VHCDR2 and VHCDR3 are respectively shown as SEQ ID NO.1, SEQ ID NO.3 and SEQ ID NO.5, and the amino acid sequences of VLCDR1, VLCDR2 and VLCDR3 are respectively shown as SEQ ID NO.2, SEQ ID NO.4 and SEQ ID NO.6. The invention further discloses a preparation method of the 5E2-12 monoclonal antibody. The invention also provides an antibody fragment of the 5E2-12 monoclonal antibody. The 5E2-12 monoclonal antibody provides a potential choice for research and development of clinical medicines for diagnosing and treating EBV latent infection and EB virus related tumors.

The invention belongs to the technical field of tumor detection, and particularly relates to a probe composition for nasopharyngeal carcinoma MRD detection, a kit and application, the probe composition for nasopharyngeal carcinoma MRD detection comprises the following probes, the sequences of the probes are SEQ IN NO.1-106; according to the targeted probe capture technology, the probe is designed according to the whole genome sequence of the EB virus, so that all EB virus sequences in a sample are captured, and the detection sensitivity and reliability are improved.

The invention belongs to the technical field of medical biology, and particularly relates to an EBV (Epstein-Barr Virus) neutralizing antibody-specifically-immune plasma high-throughput screening method and application thereof. EB virus envelope glycoprotein gp350 is selected as a screening target antigen, EBV specific plasma containing a high-titer EBV neutralizing antibody is rapidly screened in a high-throughput mode and used for preparing EBV specific human immune globulin, the titer of the EBV neutralizing antibody is obviously higher than that of listed intravenous gamma-C products, and the content of the EBV neutralizing antibody is about 4-8 times that of the EBV neutralizing antibody with the same concentration. The method provided by the invention can realize large-scale collection of EBV specific plasma through rapid high-throughput screening, reduces the workload of plasma screening, is suitable for large-scale production of EBV specific human immune globulin, and has a good application prospect.

The present application relates to a detection kit for the diagnosis and screening of nasopharyngeal carcinoma. The detection kit comprises an immunochromatography detection card, and the immunochromatography detection card comprises a reagent for detecting an EB virus antigen-antibody by means of a colloidal gold labeling method. The present application further relates to the use of the detection card and the EB virus antigen-antibody in the preparation of a detection kit or detection card for the diagnosis and screening of nasopharyngeal carcinoma.

The invention relates to the technical field of kits, and discloses an EB (Epstein-Barr) virus detection kit, which comprises a virus detection kit based on combined use of a PCR (Polymerase Chain Reaction) isothermal amplification technology (RPA) and a magnetic particle chemiluminescence technology, the kit consists of a sample releasing agent, a standard solution, a quality control solution, a PCR amplification system and magnetic beads, and has a function of quantitatively detecting EB viruses in a sample. The kit is composed of a sample releasing agent, a standard solution, a quality control solution, a PCR amplification system and magnetic beads, and matched reagents are composed of a substrate solution A, a substrate solution B and a cleaning solution. Compared with conventional PCR (polymerase chain reaction), the EB virus detection kit has the following characteristics that a full-automatic detection process is adopted, so that personal errors are reduced; the detection process is cleaned in three steps, the detection specificity is improved, background signals are reduced, and the detection sensitivity is enhanced; the detection time is shortened to be within 35 minutes, the virus load can be directly detected, the method is suitable for large-batch sample screening, and the detection and screening efficiency is improved.

Disclosed are a monoclonal antibody Fab5 recognizing the gB protein of EB viruses and the use thereof, belonging to the technical field of antibodies. The monoclonal antibody or an antigen-binding fragment thereof has high affinity for the gB protein and can significantly inhibit the EB virus infection of epithelial cells and B cells, and the epitope of the Fab5 binding to the gB is clarified by structural analysis. The antibody can be used for detecting the presence or level of the gB protein in specimens, detecting EB viruses, diagnosing diseases caused by EB virus infection, preventing EB virus infection, and / or treating and / or preventing diseases caused by EB virus infection.

The invention relates to a fusion immunogen and application thereof in preparation of a self-replicating mRNA vaccine infected by EBV, and belongs to the technical field of biological medicine. The fusion immunogen is composed of a signal peptide, an EB virus latency period protein, a linker and an MITD structure. The EB virus incubation period protein is selected from one or more of EBNA1, EBNA3A, LMP1 and LMP2. The fusion immunogen can be used for constructing a self-replicating mRNA vaccine, can induce an organism to generate specific humoral immunity and cellular immunity response, and is suitable for prevention and treatment of EBV related diseases.

The invention discloses an EB virus related B cell lymphoma diagnostic kit based on GNAS methylation detection. The invention provides a new marker for diagnosis of EB virus related B cell lymphoma, provides a matched and verified special detection primer, and performs functional reverse verification of 5-aza-2 '-deoxycytidine drug intervention. According to the invention, the potential value of the marker in the aspect of curative effect prediction is defined, and a possible molecular basis is provided for implementing individualized demethylation treatment clinically.

The invention provides a primer probe combination, a kit and application thereof. The primer probe combination comprises at least one of a first primer probe combination, a second primer probe combination, a third primer probe combination, a fourth primer probe combination and a fifth primer probe combination; the primer probe combination is mainly used for detecting the EB virus.

The invention discloses a human EB (Epstein-Barr) virus targeting chimeric antigen receptor CAR, a CAR-NK cell and application, and the human EB virus targeting chimeric antigen receptor CAR comprises the following structure: a gH / gL single-chain antibody aiming at EB virus, a transmembrane region and an intracellular signal transduction region. The targeted human EB virus CAR-NK cell provided by the invention can effectively identify and kill nasopharyngeal carcinoma and B lymphoma infected by EBV, effectively kills tumor cells, can generate lasting immune response ability, does not generate serious toxic and side effects, and is beneficial to preventing tumor recurrence.

The invention relates to an EB (Epstein-Barr) virus infected lymphoid tissue epithelial-mesenchymal transition detection kit as well as a preparation method and application thereof. The EB virus infected lymphoid tissue epithelial-mesenchymal transition detection kit comprises a colloidal quantum well labeled probe EBER, a colloidal quantum well labeled antibody CLDN4 and a colloidal quantum well labeled antibody N-cadherin, a colloidal quantum well-probe / antibody conjugate is used for sequentially dyeing a lymphatic tissue section and marking EMT-related antigens expressed in the section, so that the qualitative or quantitative treatment of the colloidal quantum well on the lymphatic tissue cells with EMT is realized, and the comprehensive evaluation on the virus infection state, the epithelial-mesenchymal transition process and the influence of the immune function of the lymphatic tissue cells can be realized.

This invention relates to immunological detection, particularly to the field of immunological diagnosis of tumors. Specifically, this invention provides a method for diagnosing nasopharyngeal carcinoma based on anti-EBV antibody levels, and a kit for using said method. This invention also provides a polypeptide encoded by the EBV BNLF2b gene for the above-mentioned diagnosis and its use in the diagnosis of nasopharyngeal carcinoma.

The present application relates to a kind of detection kits for EB virus and plasma cell in lymphoid tissue microenvironment and its preparation method and application, kit includes colloidal quantum well labeled probe EBER, colloidal quantum well labeled antibody CD138 and colloidal quantum well labeled antibody MUM-1;By colloidal quantum well and specific antibody conjugate to thymoma paraffin section sample dyeing, conjugate can be expressed with EBER and related antigen specific connection in section, so as to realize colloidal quantum well to lymphoid tissue, EB virus and the quantity and spatial position detection of plasma cell.Colloidal quantum well replaces fluorescent dye, can realize the direct marking of tissue section, realizes the local positioning of EB virus and plasma cell in lymphoid tissue microenvironment, both can realize the detection of quantity also can realize the detection of position, it is convenient to evaluate the situation of plasma cell in EB virus infection tissue microenvironment.

The invention discloses a reagent and a kit for detecting EB (Epstein-Barr) virus infection and a method for detecting EB virus infected cell lineage, and belongs to the field of medical diagnosis. The technical problem to be solved by the invention is how to accurately locate different cell lineages of EBER + cells. The reagent for detecting EB virus infection disclosed by the invention contains an EBV probe and an antibody for marking a cell lineage, the sequence of the EBV probe is shown as SEQ ID No.1 and SEQ ID No.2, and the antibody for marking the cell lineage is a CD3 antibody, a CD20 antibody and / or a CD56 antibody. The reagent and the kit for detecting EB virus infection can be used for simultaneous marking of EBER genes and antigen proteins, accurate positioning of different cell lineages of EBER + cells is achieved, and cell lineage positioning of EB virus infection is further achieved.

The present application relates to a kind of EB virus infection lymphatic epithelial-mesenchymal transition detection kit and its preparation method and application, including colloidal quantum well labeled probe EBER, colloidal quantum well labeled antibody CLDN4, colloidal quantum well labeled antibody N-cadherin;By colloidal quantum well-probe / antibody conjugate in turn to the staining of lymphatic tissue section, the EMT-related antigen expressed in section is marked, so as to realize colloidal quantum well to the qualitative or quantitative of lymphatic tissue cell that EMT occurs, can realize the comprehensive evaluation to virus infection state, epithelial-mesenchymal transition process and its immune function influence.

The application belongs to the technical field of antibodies, and discloses a monoclonal antibody 5E9 for recognizing human R9AP protein and application thereof. The monoclonal antibody or antigen binding fragment thereof has high affinity to R9AP protein and can significantly inhibit EBV infection on epithelial cells and B cells. The antibody can be used for detecting the presence or level of R9AP protein in a sample, detecting diseases caused by high expression of R9AP, and preventing EB virus infection and / or treating and / or preventing diseases caused by EB virus infection.

The present invention relates to the technical field of antibodies. Disclosed are a monoclonal antibody 5E9 for recognizing a human R9AP and a use thereof. The monoclonal antibody or an antigen-binding fragment thereof has a high affinity to an R9AP and can significantly inhibit the infection of EB virus (EBV) on epithelial cells and B cells. The antibody can be used for detecting the presence or level of the R9AP in a sample, detecting diseases caused by high expression of the R9AP and preventing EBV infections and / or treating and / or preventing diseases caused by EBV infections.

The invention belongs to the technical field of biological medicine, and particularly relates to an EB virus related antigen long peptide and application thereof. The invention provides an EBV (Epstein-Barr Virus) related antigen long peptide. The sequence of the EBV related antigen long peptide is shown as any one of SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.14, SEQ ID NO.15, SEQ ID NO.16 or SEQ ID NO.21. The invention further provides a preparation method of the EBV related antigen long peptide. According to the research, the residence time and the immunogenicity of the long peptide in vivo are further improved by modifying the long peptide with serum albumin through the screened long peptide capable of remarkably enhancing the immunogenicity. Besides, nanoparticles of the long peptide are also constructed through an antigen-adjuvant self-assembly strategy, and the nanoparticles not only optimize the solubility and stability of the long peptide, but also enhance the antigen presentation efficiency and induce stronger immune response. The nano-particles can be combined with an immune checkpoint inhibitor to further enhance the tumor treatment effect, and the nano-particles have good safety and good application prospects and value.

The invention relates to a probe composition for detecting intracellular EBV, the probe composition comprises a basic probe and a fluorescent probe, the basic probe is hybridized and paired with intracellular EBV virus mRNA, and the fluorescent probe is hybridized and paired with the basic probe; the mRNA corresponds to an EBV virus lysis period and / or incubation period gene region. The probe composition disclosed by the invention can be widely applied to EB diagnostic reagents, curative effect evaluation and / or safe drug withdrawal of anti-EB virus treatment, and treatment endpoint monitoring of the EB virus diagnostic reagents.

The invention discloses a preparation method and application of a ZIF-8-EGCG / Co < 2 + >-coated ZnPc nano composite material. A ZIF-8 metal organic framework is used as a main body, EGCG, Co < 2 + > ions and a ZnPc photosensitizer are subjected to functional modification, and the EB virus targeted recognition capability and antibacterial activity of EGCG, the Fenton-like catalytic characteristic of Co < 2 + > and the photodynamic effect of ZnPc are further integrated on the basis of ensuring the remarkable surface area characteristic, the adjustable pore structure and the excellent biocompatibility of the composite material. Through an acid response trigger mechanism, directional enrichment and controllable release of drugs at tumor sites are realized, synergistically enhanced ROS is generated, tumor cell death is effectively induced, microbial colonization closely related to nasopharyngeal carcinoma occurrence and development is inhibited, and the drug effect is improved. An innovative solution is provided for overcoming the clinical challenges that a traditional operation is difficult to eradicate tiny focuses, and normal tissue damage is easily caused.

The invention relates to a detection kit for EB (Epstein-Barr) virus and plasma cells in a lymphatic tissue microenvironment as well as a preparation method and application of the detection kit. The kit comprises a colloidal quantum well labeled probe EBER, a colloidal quantum well labeled antibody CD138 and a colloidal quantum well labeled antibody MUM-1, a colloidal quantum well and a specific antibody conjugate are used for dyeing a thymoma paraffin section sample, and the conjugate can be specifically connected with EBER expressed in the section and related antigens, so that the colloidal quantum well can detect the number and spatial position of EB viruses and plasma cells in lymphatic tissues. The colloidal quantum well is used for replacing fluorescent dye, direct marking of tissue slices can be achieved, local positioning of EB viruses and plasma cells in the lymph tissue microenvironment is achieved, number detection and position detection can be achieved, and the situation of the plasma cells in the tissue microenvironment infected by the EB viruses can be evaluated conveniently.

The invention provides EB (Epstein-Barr) virus nucleic acid detection primers, a probe and a kit, according to a target sequence of an EB virus gene, the sequences of the primers and the probe in an asymmetric primer ERA detection system are designed and screened, and the ratio of upstream and downstream primers and an amplification reaction system are optimized, so that the EB virus nucleic acid sequence can be specifically identified, and the EB virus nucleic acid detection kit has the advantages of high specificity and high sensitivity. Non-specific binding with other irrelevant nucleic acids is reduced, so that the detection specificity is improved; meanwhile, efficient amplification of EB virus nucleic acid is realized, and the EB virus nucleic acid can be accurately detected even under the condition that the content of the virus nucleic acid is extremely low, so that the detection sensitivity and the amplification efficiency are improved.